> ## Content Index > Fetch the complete content index at: https://newsletters.qs.com/llms.txt > Use this file to discover other available public pages before exploring further. # 💊 Health Futures #37 - URL: https://newsletters.qs.com/health-futures-37/ - Published: 2024-09-30T11:30:30.000Z - Updated: 2024-09-30T11:30:29.000Z - Description: HolonIQ's Health Newsletter covers the latest developments in diagnosis technology, targeted chronic disease management, and clinical trials and highlights the week's top health deals. - Author: QS - Tags: Health Skills **Happy Monday 👋** This week's health news features Targeted Chronic Disease Management, Diagnosis Technology, and Clinical Trials. In Targeted Chronic Disease Management, Novo Nordisk showed [promising](https://www.biospace.com/drug-development/novos-next-gen-cb1-drug-leads-to-weight-loss-in-phase-ii-but-neuropsychiatric-events-reported?ref=newsletters.qs.com) results in a Phase IIa trial for the obesity drug ‘monlunabant’. The pharmaceutical company plans to conduct further studies to assess its safety and efficacy. In diagnosis technology, GE HealthCare[ launched](https://finance.yahoo.com/news/ge-healthcare-shares-rise-ai-145800277.html?ref=newsletters.qs.com) Venue Sprint, a new portable ultrasound system designed to meet the demand for point-of-care ultrasound and offers high-quality imaging, AI-enabled tools, and intuitive documentation tools. In clinical trials, Summit Therapeutics[ improved](https://seekingalpha.com/article/4722139-summit-therapeutics-bests-mercks-top-selling-drug-in-phase-iii-trial?ref=newsletters.qs.com) efficacy over Merck’s Keyturda in phase III trials. The drug's dual mechanism targeting PD-1 and VEGF could disrupt the oncology market, similar to Regeneron's Eylea. In health funding, Telix Pharmaceuticals acquiredRLS Radiopharmacies for [$230M](https://www.biospectrumasia.com/news/25/24925/australias-telix-pharma-buys-rls-usa-for-230-m-to-build-next-gen-radiometal-production-network.html?ref=newsletters.qs.com) expanding its manufacturing and distribution footprint in North America. ## 🎯 Targeted Chronic Disease Management 🧪 **Novo Nordisk showed**[ **promising**](https://www.biospace.com/drug-development/novos-next-gen-cb1-drug-leads-to-weight-loss-in-phase-ii-but-neuropsychiatric-events-reported?ref=newsletters.qs.com) **results in a Phase IIa trial for obesity.** In the trial, patients treated with ‘monlunabant,’ a cannabinoid receptor 1 inverse agonist, experienced significant weight loss compared to placebo. 💊 **Halia Therapeutics announced** [**positive**](https://www.prnewswire.com/news-releases/halia-therapeutics-reveals-promising-preclinical-obesity-data-ht-6184-and-semaglutide-combination-enhances-weight-loss-and-preserves-lean-muscle-mass-302254759.html?ref=newsletters.qs.com) **preclinical results for HT-6184 combined with semaglutide in treating obesity.** HT-6184 targets inflammation, a key driver of obesity-related metabolic dysfunction. **🩸 New blood test to** [**identify**](https://health.economictimes.indiatimes.com/news/diagnostics/blood-test-could-identify-children-at-risk-of-obesity-related-conditions-lipid-analysis-suggests/113599546?ref=newsletters.qs.com) **diabetes risk in children.** A new blood test helped identify children at risk of obesity-related conditions by assessing a broader range of lipid molecules. ## 🌐 Diagnosis Technology 🤖 **Huawei** [**teamed up**](https://www.prnewswire.com/news-releases/huawei-launches-medical-technology-digitalization-2-0-solution-facilitating-precision-healthcare-with-ai-302255035.html?ref=newsletters.qs.com) **with partners to launch the Medical Technology Digitalization 2.0 Solution.** The solution uses AI-assisted diagnosis and intelligent quality control to improve the quality and efficiency of healthcare services. 👶 **GE HealthCare**[ **launched**](https://finance.yahoo.com/news/ge-healthcare-shares-rise-ai-145800277.html?ref=newsletters.qs.com) **the Venue Sprint, a new portable ultrasound system.** The device is designed to meet the growing demand for point-of-care ultrasound and offers high-quality imaging, AI-enabled tools, and intuitive documentation tools. 🐟 **XpertDox** [**partners**](https://www.prnewswire.com/news-releases/xpertdox-partners-with-blue-fish-pediatrics-to-enhance-medical-coding-efficiency-with-ai-powered-healthcare-coding-software-302253691.html?ref=newsletters.qs.com) **with Blue Fish Pediatrics.** This partnership aims to implement XpertCoding, an AI-powered medical coding platform to enhance efficiency, accuracy, and clinical documentation at Blue Fish Pediatrics' clinics. ## 🧬 Clinical Trials 🔬 **Sanofi's ‘tolebrutinib’** [**showed**](https://www.biospace.com/drug-development/sanofis-tolebrutinib-delays-ms-progression-in-phase-iii-study-following-earlier-flops?ref=newsletters.qs.com) **promising results in a Phase III trial for non-relapsing secondary progressive multiple sclerosis.** The drug delayed the onset of disability progression by 31% in patients with this condition. 🧫 **Proteomics International** [**reported**](https://www.medicaldevice-network.com/news/proteomics-rpromarkereso-test/?cf-view&ref=newsletters.qs.com) **positive results for the PromarkerEso oesophageal cancer test.** This test is targeted for the early detection and treatment of the illness, a predominant form of esophageal cancer. 🎗️ **Summit Therapeutics**[ **outperformed**](https://seekingalpha.com/article/4722139-summit-therapeutics-bests-mercks-top-selling-drug-in-phase-iii-trial?ref=newsletters.qs.com) **Merck's cancer drug in Phase III trials.** Summit drug, ‘ivonescimab’ showed improved efficacy over Merck’s Keytruda targeting both PD-1 and VEGF. ## **💰** Deals of the Week 📻 **Telix Pharmaceuticals** acquired **RLS Radiopharmacies** for [$230M](https://www.biospectrumasia.com/news/25/24925/australias-telix-pharma-buys-rls-usa-for-230-m-to-build-next-gen-radiometal-production-network.html?ref=newsletters.qs.com). The acquisition intends to meet the current growing demand for diagnostic and therapeutic radiopharmaceuticals. 🏥 **Alan,** a France-based health insurer, raised [$192M](https://www.finsmes.com/2024/09/alan-raises-e173m-in-series-f-funding.html?ref=newsletters.qs.com) in Series F funding at a $4.5B valuation. The company plans to use the funds to expand operations and development efforts. 🧬 **Vicebio**, a biopharmaceutical company, raised [$100M](https://www.finsmes.com/2024/09/vicebio-raises-100m-in-series-b-financing.html?ref=newsletters.qs.com#google%5Fvignette) in Series B funding. The company intends to accelerate the development of multivalent respiratory virus vaccines using proprietary molecular clamp technology. 💊 **Ahammune Biosciences** raised [$5M](https://yourstory.com/2024/09/ahammune-biosciences-bags-5m-series-funding-biotech-startup?ref=newsletters.qs.com) in a Series A funding round led by early-stage venture fund pi Ventures. The capital is used to help conduct Phase II human clinical trials for its vitiligo drug candidate. 💉 **Helix Labs** secured[ $2M](https://www.finsmes.com/2024/09/helix-labs-raises-2m-in-pre-seed-funding.html?ref=newsletters.qs.com#google%5Fvignette) in Pre-Seed funding. The company plans to use the funds to expand operations and its development efforts. --- **Thank you for reading. Have a great week ahead!** Have some feedback or suggestions? Let us know at hello@holoniq.com [ ](https://newsletters.qs.com/psychedelic-mental-health-treatments-south-asia-health-tech-100-2/)